Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 3/20 | 0.31 |
| ▸ | JAK3 | P52333 | 3/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | TYK2 | P29597 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6370773 | 0.76 | DYRK1A (0.44) | KDM4E | |
| SCHEMBL19154030 | 0.75 | CYP11B2 (0.36) | CYP11B2JAK2JAK3KDM4E | |
| SCHEMBL12309185 | 0.72 | RBP4 (0.33) | KDM4E | |
| SCHEMBL21025444 | 0.70 | GRN (0.32) | CYP11B2JAK2JAK3KDM4E | |
| SCHEMBL18238520 | 0.70 | CYP11B2 (0.33) | CYP11B2JAK2JAK3JAK1TYK2 | |
| SCHEMBL15679454 | 0.69 | KDM4E (0.35) | KDM4E | |
| SCHEMBL6202914 | 0.67 | PDE10A (0.33) | — | |
| Hydrochloric Acid SCHEMBL1605985 | 0.64 | PDE10A (0.32) | — | |
| SCHEMBL10220083 | 0.64 | JAK2 (0.46) | CYP11B2JAK2JAK3KDM4E | |
| SCHEMBL10129490 | 0.64 | SSTR4 (0.48) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20210355119-A1 | CYANO QUINOLINE AMIDE COMPOUNDS AS HER2 INHIBITORS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2021-11-18 | — | — | US | disclosed |
| US-10683297-B2 | Substituted heteroaryl compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190152977-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | Northern Industrial Area, (CN) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | ERBB2, EGFR, ERBB3 | CYP11B2 4076/4885JAK2 164/4885JAK3 1624/4885 |
| US-20190152977-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | PRKACA, PRKDC, PRKACB | CYP11B2 446/4885JAK2 214/4885JAK3 181/4885 |
| US-10683297-B2 | Substituted heteroaryl compounds and methods of use | PRKACA, PRKDC, PRKACB | CYP11B2 446/4885JAK2 214/4885JAK3 181/4885 |
| US-20210355119-A1 | CYANO QUINOLINE AMIDE COMPOUNDS AS HER2 INHIBITORS AND METHODS OF USE | ERBB2, EGFR, ERBB3 | CYP11B2 4137/4885JAK2 172/4885JAK3 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.